Fax: (773) 834-3538
A pilot study of the vulnerable elders survey-13 compared with the comprehensive geriatric assessment for identifying disability in older patients with prostate cancer who receive androgen ablation†
Article first published online: 11 JAN 2007
Copyright © 2007 American Cancer Society
Volume 109, Issue 4, pages 802–810, 15 February 2007
How to Cite
Mohile, S. G., Bylow, K., Dale, W., Dignam, J., Martin, K., Petrylak, D. P., Stadler, W. M. and Rodin, M. (2007), A pilot study of the vulnerable elders survey-13 compared with the comprehensive geriatric assessment for identifying disability in older patients with prostate cancer who receive androgen ablation. Cancer, 109: 802–810. doi: 10.1002/cncr.22495
Presented in part as a poster at the Annual Meeting of the American Society of Clinical Oncology, Atlanta, Georgia, June 2–6, 2006.
- Issue published online: 2 FEB 2007
- Article first published online: 11 JAN 2007
- Manuscript Accepted: 20 NOV 2006
- Manuscript Revised: 16 NOV 2006
- Manuscript Received: 15 AUG 2006
- American Society of Clinical Oncology Young Investigator Award (to S.G.M.)
- geriatric assessment;
- prostate cancer;
- vulnerable elders;
- functional impairment
Impairments in geriatric domains adversely affect health outcomes of the elderly. The Comprehensive Geriatric Assessment (CGA) is a key component of the treatment approach for older cancer patients, but it is time consuming. In this pilot study, the authors evaluated the validity of a brief, functionally based screening tool, the Vulnerable Elders Survey-13 (VES-13), for identifying older patients with prostate cancer (PCa) with impairment in the oncology clinic setting.
Patients with PCa aged ≥70 years who actively were receiving androgen ablation treatment and who were followed within the clinics at the University of Chicago were eligible. Patients self-completed the VES-13 and CGA instruments and repeated the VES-13 1 month later. Physical performance and cognitive assessments were administered by a research assistant.
Of 50 participating patients, 50% were identified as impaired by the VES-13 (score ≥3). Sixty percent of patients scored as impaired on ≥2 tests within the CGA, exhibiting deficits in multiple domains. The reliability of the VES-13 (Pearson correlation coefficient) was 0.92. The cut-off score of 3 on the VES-13 had 72.7% sensitivity and 85.7% specificity for CGA deficits and was highly predictive for identifying impairment (area under the receiver operating characteristic curve, 0.90). Patients who had mean VES-13 scores ≥3 performed significantly worse on evaluations of activities of daily living (P = .001), physical performance (P = .002), comorbidity (P = .004), and cognitive impairment (P = .003).
Functional and cognitive impairments are highly prevalent among older patients with PCa who receive androgen ablation in oncology clinics. The current results indicated that the brief VES-13 performed nearly as well as a conventional CGA in detecting geriatric impairment in this population. Cancer 2007. © 2007 American Cancer Society.